Table 3.
Cox Proportional Hazard Models of Diagnostic, and Treatment Variables on Outcomes in 217 Patientsa
| Outcome
|
||||||||
|---|---|---|---|---|---|---|---|---|
| Locoregional Recurrence (47 Events)
|
Distant Metastasis (38 Events)
|
All-Cause Mortality (147 Events)
|
Disease-Specific Mortality (56 Events)
|
|||||
| AHR (95% CI) | Events, No. | AHR (95% CI) | Events, No. | AHR (95% CI) | Events, No. | AHR (95% CI) | Events, No. | |
| Diagnostic Variablesb | ||||||||
|
| ||||||||
| Computed tomography | ||||||||
|
| ||||||||
| None | 1 [Reference] | 26 | 1 [Reference] | 17 | 1 [Reference] | 64 | 1 [Reference] | 16 |
|
| ||||||||
| Yes | 0.6 (0.3–1.3) | 21 | 0.6 (0.3–1.4) | 21 | 0.9 (0.6–1.4) | 83 | 1.0 (0.5–2.1) | 40 |
|
| ||||||||
| Positron emission tomography | ||||||||
|
| ||||||||
| None | 1 [Reference] | 43 | 1 [Reference] | 28 | 1 [Reference] | 120 | 1 [Reference] | 40 |
|
| ||||||||
| Yes | 0.4 (0.1–1.2) | 4 | 1.1 (0.5–2.5) | 10 | 0.7 (0.4–1.2) | 27 | 1.2 (0.6–2.3) | 16 |
|
| ||||||||
| Pathologic nodal evaluation | ||||||||
|
| ||||||||
| None | 1 [Reference] | 33 | 1 [Reference] | 21 | 1 [Reference] | 103 | 1 [Reference] | 35 |
|
| ||||||||
| SLNB only | 0.4 (0.2–1.2) | 5 | 1.1 (0.4–3.1) | 7 | 0.4 (0.2–0.7) | 13 | 0.4 (0.1–1.1) | 6 |
|
| ||||||||
| LAD only | 0.4 (0.4–1.2) | 5 | 1.2 (0.4–3.6) | 7 | 0.8 (0.5–1.4) | 24 | 0.8 (0.3–1.8) | 13 |
|
| ||||||||
| Both | 0.4 (0.1–1.6) | 4 | 0.2 (0.0–1.0)c | 3 | 0.2 (0.1–0.5) | 7 | 0.1 (0.0–0.4) | 2 |
|
| ||||||||
| Treatment Variablesb | ||||||||
|
| ||||||||
| Surgery | ||||||||
|
| ||||||||
| None | 1 [Reference] | 12 | 1 [Reference] | 10 | 1 [Reference] | 49 | 1 [Reference] | 24 |
|
| ||||||||
| With clear margins | 1.1 (0.5–2.4) | 29 | 0.6 (0.2–1.7) | 25 | 0.7 (0.4–1.1) | 82 | 0.8 (0.3–1.8) | 26 |
|
| ||||||||
| With margin not clear/missing | 1.7 (0.6–5.3) | 6 | 0.7 (0.2–3.4) | 3 | 1.9 (1.0–3.9)d | 16 | 1.5 (0.5–4.4) | 6 |
|
| ||||||||
| Radiation therapy | ||||||||
|
| ||||||||
| None | 1 [Reference] | 37 | 1 [Reference] | 19 | 1 [Reference] | 90 | 1 [Reference] | 33 |
|
| ||||||||
| Yes | 0.3 (0.1–0.6) | 10 | 1.5 (0.8–3.1) | 19 | 0.9 (0.6–1.3) | 57 | 0.8 (0.4–1.5) | 23 |
|
| ||||||||
| Chemotherapy | ||||||||
|
| ||||||||
| None | 1 [Reference] | 43 | 1 [Reference] | 32 | 1 [Reference] | 130 | 1 [Reference] | 46 |
|
| ||||||||
| Yes | 0.5 (0.2–1.7) | 4 | 1.9 (0.6. 5.8) | 6 | 1.2 (0.6–2.2) | 17 | 0.9 (0.4–2.3) | 1 |
Abbreviations: AHR, adjusted hazard ratio; LAD, lymphadenectomy; SLNB, sentinel lymph node biopsy.
a
Adjusted for all other variables listed in table, except the race variable, which is excluded due to sparse data in nonwhite strata. One individual with no staging data was excluded from all adjusted models. The 95% CIs were calculated using the Wald method.
b
Defined as part of the initial diagnostic process or within 3 months after the initial diagnosis.
c
P = .05.
d
P = .07.